(Reuters) - The ruling prevents the defendants from obtaining U.S. Food and Drug Administration approval to market a generic version of Allergan's product Acular, for temporary relief of eye itching associated with seasonal allergic conjunctivitis.
In 2006 the defendants appealed a ruling by the U.S.District Court for the Northern District of California that the defendants' proposed generic product infringed a patent owned by Roche Palo Alto LLC and licensed to Allergan.
Read more at Reuters.com Government Filings News
In 2006 the defendants appealed a ruling by the U.S.District Court for the Northern District of California that the defendants' proposed generic product infringed a patent owned by Roche Palo Alto LLC and licensed to Allergan.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment